The point of care infectious disease market caters to various end users, including homecare settings, hospitals, diagnostic centers, outpatient healthcare settings, and more. With a focus on accessibility, distribution channels involve direct tenders for institutional procurement and retail sales for individual consumers. This diverse approach ensures that the market effectively reaches different healthcare settings, providing essential infectious disease testing solutions directly through institutional tenders and retail avenues, addressing the specific needs of both professional healthcare providers and individuals.
Access Full Report@ https://www.databridgemarketresearch.com/reports/latin-america-point-of-care-infectious-disease-market
Data Bridge Market Research analyses that the Latin America Point of Care Infectious Disease Market, which was USD 1.3 billion in 2021, is expected to reach USD 1.96 billion by 2029, and is expected to undergo a CAGR of 5.24% during the forecast period 2022 to 2029. The driver of market expansion in point-of-care infectious disease testing lies in heightened awareness and improved accessibility. Increased knowledge about the benefits of on-the-spot testing, coupled with enhanced availability, propels the global expansion of these essential healthcare solutions.
Key Findings of the Study
Government initiatives is expected to drive the market's growth rate
Government initiatives play a crucial role in propelling the growth of the Point of care infectious disease market. Supportive policies and programs aimed at promoting point-of-care testing align with public health priorities. By fostering accessibility, these initiatives enhance the adoption of rapid diagnostics, ensuring timely and effective disease management. As governments prioritize preventive healthcare, their active involvement contributes significantly to the expansion of point-of-care infectious disease testing, addressing critical health challenges more efficiently.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014-2019)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Products and Services), Technology (Immunodiagnostics, Molecular Diagnostics, Dipsticks, Microfluidics and Others), Application (Tropical Diseases, Sexually Transmitted Disease, Respiratory Disorders, Liver Disorders, Inflammatory Diseases, Hospital Acquired Infections (HAIS), GI Infections, CNS Infections, Cardiovascular Infection and Others), Availability (Over-the-Counter (OTC) Testing Kits and Prescription-Based Testing Kits), End-User (Homecare Setting, Hospitals, Diagnostic Centres, Outpatient Healthcare Setting and Others),Distribution Channel (Direct Tenders and Retail Sales)
|
|
Countries Covered
|
Brazil, Argentina and Rest of Latin America as part of Latin America.
|
|
Market Players Covered
|
Abbott (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), BD (U.S.), Siemens Healthcare Private Limited (Germany), Bio-Rad Laboratories, Inc. (U.S.), Danaher (U.S.), Sekisui Diagnostics (U.S.), Trinity Biotech (Ireland), bioMérieux (France), EKF Diagnostics (Germany), AccuBioTech Co., Ltd. (China), Instrumentation Laboratory (U.S.), Beckman Coulter, Inc. (U.S.), PTS Diagnostics (U.S.), Nova Biomedical (U.S.), Chembio Diagnostics, Inc. (U.S.), Quidel Corporation (U.S.) and Sienco, Inc (U.S.)
|
|
Data Points Covered in the Report
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
|
Segment Analysis:
The Latin America point of care infectious disease market is segmented on the basis of type, technology, availability, application, distribution channel and end-user.
- On the basis of type, the Latin America point of care infectious disease market is segmented into products and services
- On the basis of technology, the Latin America point of care infectious disease market is segmented into immunodiagnostics, molecular diagnostics, dipsticks, microfluidics and others
- On the basis of availability, the Latin America point of care infectious disease market is segmented into over-the-counter (OTC) testing kits and prescription-based testing kits
- On the basis of application, the Latin America point of care infectious disease market is segmented into tropical diseases, sexually transmitted disease, respiratory disorders, liver disorders, inflammatory diseases, hospital acquired infections (HAIS), GI infections, CNS infections, cardiovascular infection and others
- On the basis of distribution channel, the Latin America point of care infectious disease market is segmented into direct tenders and retail sales
- On the basis of end-user, the Latin America point of care infectious disease market is segmented into homecare setting, hospitals, diagnostic centres, outpatient healthcare setting and others
Major Players
Data Bridge Market Research recognizes the following companies as the Latin America point of care infectious disease market players in Latin America point of care infectious disease market are Abbott (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), BD (U.S.), Siemens Healthcare Private Limited (Germany), Bio-Rad Laboratories, Inc. (U.S.), Danaher (U.S.).
Market Developments
- In January 2023, Cipla Inc. launched "Cippoint," a point-of-care testing device, marking a significant entry into the point of care infectious disease market. This innovative device enhances accessibility to rapid diagnostics, highlighting Cipla's commitment to addressing healthcare challenges. The launch strengthens their position in the market and meets the growing demand for convenient infectious disease testing solutions
- In March 2020, LumiraDx Limited's collaboration with Chembio Diagnostics to develop a COVID-19 point-of-care test marked a strategic move into the point of care infectious disease market. This joint effort positions LumiraDx to enter a new market segment, capitalizing on the urgent need for accessible and rapid diagnostic solutions during the global COVID-19 pandemic
- In March 2020, Abbott's launch of a rapid molecular point-of-care test for detecting the novel coronavirus in just five minutes marked a significant breakthrough in the point of care infectious disease market. Operating on the ID NOW platform, this innovation addressed the urgent need for swift and accessible COVID-19 testing during the global pandemic, enhancing Abbott's industry standing
- In February 2020, Nanopin and ThermoFisher partnered to enhance infectious disease detection technologies, providing ThermoFisher with a new platform for expansion in the point of care infectious disease market. This strategic partnership positions ThermoFisher to leverage Nanopin's expertise, strengthening its presence in the rapidly growing point-of-care market for infectious diseases
- In January 2020, F. Hoffmann-La Roche Ltd initiated a 15-year partnership with Illumina to advance the use of distributable next-generation sequencing (NGS) testing in oncology. This partnership leverages the strengths of both companies, aiming to enhance the global adoption of NGS in cancer care within the point of care infectious disease market, addressing critical healthcare needs
Regional Analysis
Geographically, the countries covered in the Latin America point of care infectious disease market report are Brazil, Argentina and Rest of Latin America as part of Latin America.
As per Data Bridge Market Research analysis:
Brazil is the dominant country in the Latin America point of care infectious disease market during the forecast period 2022-2029
Brazil dominates the point of care infectious disease market is driven by robust government initiatives aimed at enhancing population health. The country faces challenges in achieving a healthy population due to the high prevalence of infectious diseases. As the government prioritizes public health improvements, the demand for rapid, accessible infectious disease testing solutions is heightened. This focus positions Brazil as a dominant force in the region, addressing critical healthcare challenges and contributing to the growth of the market
For more detailed information about the Latin America point of care infectious disease market report, click here – https://www.databridgemarketresearch.com/reports/latin-america-point-of-care-infectious-disease-market
